In another case, a patient presenting with an FGFR2–SORBS1 gene fusion achieved a maximum tumour burden reduction of 68% from baseline to third-line treatment with the pan-FGFR inhibitor futibatinib after developing resistance to infigratinib and Debio 1347. The gene discussed is FGFR2; the disease is neoplasm.